Research published in the journal Genetics suggests that sertraline targets intracellular membranes of yeast cells that don’t express the known therapeutic target, suggesting a secondary drug target or pathwayA new discovery about selective serotonin reuptake inhibitors (SSRIs) suggests that these drugs, which are used to treat mental health disorders like depression and anxiety, have multiple …

( Genetics Society of America ) A new discovery about selective serotonin reuptake inhibitors suggests that these drugs, used to treat mental health disorders like depression and anxiety, have multiple effects on our cells. Researchers used yeast cells to identify secondary drug targets or pathways affected by SSRIs. Such secondary pathways could help explain why different people taking the same …

Throughout the past three years at MSU, bacterial life has been Ben Rollers 40-hour-a-week obsession. A third year microbiology and molecular genetics graduate student at MSU, Roller has been researching various aspects of the bacterial life cycle since he was an undergraduate student at the University of Minnesota. Thanks to a more than $150,000 fellowship, Roller will have another three years …

Have wheat breeders reached the maximum potential for grain yield?

A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair. The study is published in the Aug. 13 edition of the journal Molecular Cell. RPA 70 is a component of multiprotein machinery called the RPA complex …

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics’ PST genetic test. PST is the Company’s genetic test brand that identifies individuals with increased risk for …

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/d0dc1b/the_top_20_develop) has announced the addition of the “The Top 20 Developers of Molecular Diagnostic Tests for Lung Cancer” report to their offering. According to the World Health Organizations International Agency for Research on Cancer, lung cancer has been the most …

NEW YORK (GenomeWeb News) The genetic testing industry has garnered much attention recently as an increase in corporate players and spread of testing has caught the eye of government regulators, and some industry watchers are beginning to consider what sort of regulatory schemes could be used to protect consumers without killing businesses and squelching innovation.

Manuela Raffatellu, M.D., Assistant Professor, Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, has been chosen by the American Society for Microbiology (ASM) to receive a 2010 ICAAC Young Investigator Award. Sponsored by the ASM, this award recognizes an early career scientist for research excellence in microbiology and infectious diseases …

NEW YORK (GenomeWeb News) Having successfully established itself in the US, Myriad Genetics this week said it will be tackling Europe as it embarks on a strategy to grow its presence internationally.

A study published in the August Journal of Nuclear Medicine (JNM) finds that molecular imaging-a non-invasive imaging procedure-can identify high-risk patients with potentially life-threatening cardiovascular conditions and help physicians determine which patients are best suited for implantable cardioverter defibrillator (ICD) therapy.

Renowned molecular geneticist and Harvard Professor, George Church will speak at the Next Generation Dx Summit to take place in Washington, DC on August 24-26. Dr. Church will discuss how the evolution of next generation sequencing technology is significantly enhancing the diagnostic landscape for infectious disease, and will offer a perspective on the need to demonstrate clear clinical benefits …

FROM a microscope and a small refrigerator to the countrys most comprehensive research laboratory on genetics. For this feat, the Institute of Human Genetics (IHG) received the 2010 Outstanding Health Research Award from the Philippine Council on Health Research and Development (PCHRD).

Myriad Genetics Inc. recorded an EPS of 54 cents in the fourth quarter, surpassing the Zacks Consensus Estimate of 33 cents.

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics’ PST genetic test. Â PST is the Company’s genetic test brand that identifies individuals with increased risk for severe and …

Molecular diagnostics company Myriad Genetics Inc. said Tuesday its fiscal fourth quarter earnings more than doubled due in part to revenue growth and a one-time income-tax benefit.

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, “Apparatus, system, and method for purifying nucleic acids” protects the Company’s use of its pioneering nucleic acid …

This bullish call comes from more than just one analyst.

LOS ANGELES–(BUSINESS WIRE)–Response Genetics Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010. Molecular diagnostic testing has been integrated into routine clinical practice and drug development. Our continued growth last quarter was …